NEW YORK (GenomeWeb News) – Diagnoplex and Unilabs said today that they have signed an agreement to commercialize Colox, Diagnoplex's minimally invasive colorectal cancer assay, within the Unilabs network.

The test will be available initially in the Swiss and Swedish markets, the companies said.

Colox, Diagnoplex's lead product, is a PCR-based test intended for the systematic screening of colorectal cancer. The gene signature underlying Colox has been designed to detect early and advanced disease stages with "outstanding results and reliability," said Diagnoplex.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.